Carbon Footprint of Medical Supplies: How PLA and Sustainable Materials Reduce Healthcare Emissions

Last updated: August 2026  |  By the CliniEco Medical Team

The environmental footprint of health care extends far beyond operating theatres. In Canada, the health-care sector accounts for roughly 4.6% of national greenhouse gas (GHG) emissions [1], and health care globally contributes approximately 4.4% of net global emissions [2]. A substantial portion of this footprint comes not from building energy alone, but from the manufacture, transport, use and disposal of the medical supplies that hospitals, clinics and long-term care facilities depend on daily.

This article examines the carbon footprint of medical supplies, explains the life-cycle assessment (LCA) methods used to measure it, and evaluates the evidence for polylactic acid (PLA) and other bio-based materials as lower-carbon alternatives — synthesizing peer-reviewed research, international standards and current regulation into a practical framework for Canadian procurement teams.

Why the Carbon Footprint of Medical Supplies Matters

Health care is among the most carbon-intensive service sectors in the developed world: Health Care Without Harm and Arup estimated its climate footprint at 4.4% of global net emissions — more than aviation and shipping combined [2]. In Canada, Eckelman and colleagues calculated that the health-care system generated about 33 million tonnes of CO2e in 2015 — 4.6% of the national total [1]. In the United Kingdom, the National Health Service accounts for roughly 4% of England's footprint, with a net-zero commitment for 2040 [4]. The WHO Global Road Map for Health Care Decarbonization names supply chains and procurement among three priority action areas [3].

Within an institution, the supply chain — pharmaceuticals, devices, consumables and packaging — can represent 40% to 70% of total emissions [4][20]. Single-use products made from fossil-based polymers dominate, and because contracts run for years, today's decisions lock in emissions. Waste matters too: about 85% of health-care waste is general and non-hazardous; 15% is hazardous and requires specific treatment [16].

Measuring Emissions: Life-Cycle Assessment Methodology

Comparing the carbon footprint of a polypropylene underpad with a PLA underpad requires a consistent method. ISO 14040 and ISO 14044 define the principles and requirements for life-cycle assessment [5][6]. An LCA quantifies material and energy flows across raw material extraction, manufacturing, distribution, use and end-of-life.

• Cradle-to-gate covers extraction through production (the factory gate) and is commonly used to compare polymers and resins.
• Cradle-to-grave extends through use and disposal — more appropriate for finished products, since end-of-life treatment can materially change results.
• Cradle-to-cradle includes recycling or composting loops that return materials to productive use.

Two further choices affect comparability: the functional unit must be equivalent (one underpad absorbing a defined fluid volume), and system boundaries and allocation rules can shift results by 10% to 30%. Environmental product declarations (EPDs) and third-party LCAs are therefore more reliable than supplier brochures [5][6]. Table 1 summarizes the stages of a typical medical disposable LCA.

Table 1. Life-cycle stages and their indicative contribution to greenhouse gas emissions for a typical single-use medical product. Ranges compiled from the LCA literature cited in [5][6][7][20].

For fossil-based polymers, published LCAs consistently show the raw material stage dominates: more than half of life-cycle GHG emissions are embedded in the resin before the product reaches a loading dock [7][20]. Material choice therefore matters enormously.

The Carbon Footprint of Common Medical Polymers

Polypropylene (PP), polyethylene (PE), polyvinyl chloride (PVC), polyethylene terephthalate (PET) and polystyrene (PS) account for the majority of single-use medical products and packaging. Table 2 presents indicative cradle-to-gate ranges from published LCAs and industry eco-profiles.

Table 2. Indicative cradle-to-gate carbon footprints of polymers used in medical supplies. Rounded ranges from published LCAs and eco-profiles [7][8][9][19]; PLA values depend on feedstock and energy mix. Incinerating one kilogram of a fossil-based polymer releases roughly 2.5–3.7 kg CO2e of fossil carbon, whereas carbon in PLA is biogenic [17].

Three observations follow. First, polymer choice spans a factor of roughly two across conventional medical plastics. Second, end-of-life treatment matters: incinerating a fossil-based polymer — the dominant route for hazardous health-care waste — releases its stored fossil carbon as CO2 [17]. Third, fibre alternatives are not automatically greener: conventional cotton carries a much higher cradle-to-gate footprint per kilogram than most polymers, though textiles can often be reused [18].

The pandemic offered a large-scale demonstration: single-use polypropylene face masks carry roughly 50–60 g CO2e each, dominated by resin production and manufacturing [25], and a systematic review of surgical operations found single-use items drive a large share of perioperative emissions [20].

Bioplastics in Health Care: PLA and PHA

"Bioplastic" covers two distinct families: bio-based plastics, produced wholly or partly from renewable feedstock, and biodegradable plastics, capable of microbial breakdown under defined conditions. A material can be one, both or neither [9]. PLA is both bio-based and, under industrial composting conditions, biodegradable. PHA, produced by bacterial fermentation, biodegrades across more environments, including marine settings, though commercial capacity remains limited [19].

PLA is synthesized from lactic acid fermented from crop sugars such as corn, cassava or sugarcane. Published inventories indicate a cradle-to-gate footprint of roughly 1.2–2.0 kg CO2e per kilogram of resin [7][8]; the 2014 Ingeo inventory reported about 1.9 kg CO2e per kilogram, with further reductions as renewable energy shares increased [7].

For medical applications, PLA is rigid, clear, printable and heat-sealable, and forms nonwovens, films and fibres. Its long history in resorbable sutures and implants evidences an established biocompatibility profile in specific device forms [8]. Biocompatibility, however, is a property of the finished device, not of the raw resin; every product intended for patient contact should be supported by testing conducted in accordance with ISO 10993-1 [23].

CliniEco Medical has built a product line around PLA nonwovens for Canadian health-care and long-term care settings, including CliniEco's PLA biodegradable underpads, PLA biodegradable bed sheets, PLA biodegradable isolation gowns and PLA biodegradable waste bags.

For buyers, the question is whether PLA products deliver equivalent performance with a lower footprint. Laboratory studies confirm PLA nonwovens possess adequate tensile strength and absorbency for their intended applications [8], and substituting a resin with a lower cradle-to-gate footprint reduces the dominant upstream share of life-cycle emissions [7]. The gown study by Vozzola and colleagues found reusable gowns generally outperform disposables, but among single-use options, material and manufacturing choices materially affect outcomes [18].

Compostability and End-of-Life: What ASTM D6400 Really Means

Compostability is a precisely defined property, not a marketing term. ASTM D6400 requires that a plastic labelled compostable disintegrate by at least 90% within 180 days, convert at least 90% of its carbon to CO2 within 180 days, and leave no ecotoxicity under industrial composting conditions — typically 58°C with controlled moisture and aeration [10]. Certification programmes such as BPI and TÜV OK Compost verify compliance [9].

Two caveats follow. First, "compostable" does not mean "biodegradable anywhere": PLA degrades slowly in soil, freshwater and marine environments, and is not reliably broken down in home heaps that fail to reach thermophilic temperatures [10][11]. Second, compostability delivers its climate benefit only if the item reaches an operating industrial composter or anaerobic digester; otherwise PLA sent to landfill resists degradation, and PLA incinerated with energy recovery releases biogenic carbon, which inventories account for differently from fossil carbon [17]. Table 3 situates composting within the waste hierarchy.

Table 3. The waste hierarchy applied to health-care materials, adapted from established Canadian and international waste policy frameworks [10][16][17][21].

Waste Management in Health Care: Treatment Routes and Their Emissions

Canadian hospitals generate general and hazardous waste. Hazardous fractions — infectious, sharp, chemical and pharmaceutical waste — are commonly treated by steam sterilization (autoclaving), chemical disinfection, microwave treatment or incineration [16]. These routes differ sharply in emissions: autoclaving and chemical treatment run at lower temperatures and produce smaller direct GHG emissions than incineration, though they consume energy and water [16][17]. Incineration, the only route that fully destroys infectious agents and sharply reduces volume, releases the fossil carbon embedded in plastics as CO2 [17].

Waste segregation is therefore environmental as well as regulatory: when non-hazardous, non-infectious items — including many PLA products — are diverted from the hazardous stream, they can be routed to recycling, organics or lower-emission treatment [16][17]. IPCC guidance recognizes that treatment choice determines whether waste contributes fossil CO2, biogenic CO2 or methane [17].

Regulatory Drivers Shaping Sustainable Procurement

In June 2022, the Government of Canada published the Single-use Plastics Prohibition Regulations (SOR/2022-136), banning the manufacture and import of six categories of single-use plastics — checkout bags, cutlery, food-service ware, ring carriers, stir sticks and straws — with sales prohibitions phased in through December 2023 [12]. The path has not been linear: in November 2023, the Federal Court found the underlying designation of "manufactured items" under the Canadian Environmental Protection Act invalid, a decision the government appealed; the case remained before the courts through 2025–2026 while Environment and Climate Change Canada developed a broader integrated management approach to plastic products [12]. The rules do not yet target medical supplies, but signal the direction of Canadian plastics policy.

The European Union has moved further. Directive (EU) 2019/904 bans certain single-use plastic products and imposes extended producer responsibility, labelling and consumption-reduction measures [13]. Medical devices are currently exempt from most provisions, yet the directive's logic — producer responsibility for end-of-life — is spreading into health-care supply chains.

The federal Greening Government Strategy commits departments and agencies to net-zero operations, with procurement as a core lever [24]. Provincial initiatives, including British Columbia's CleanBC, Quebec's Plan pour une économie verte 2030 and Ontario's climate plans, encourage green procurement across the broader public sector [24], and networks such as the Canadian Coalition for Green Health Care help hospitals benchmark sustainable procurement programs [22].

Practical Procurement Strategies for Canadian Health-Care Buyers

Translating the evidence into action, procurement teams can adopt six practices:

1. Require evidence, not adjectives. Ask suppliers for EPDs or third-party LCAs per ISO 14040/14044 [5][6], and for certifications such as ASTM D6400 [10]. Treat unverified claims as unverified.
2. Start with high-volume, low-clinical-risk categories. Underpads, bed sheets, isolation gowns and waste bags are high-volume, non-sterile items with PLA alternatives available today. CliniEco's PLA biodegradable underpads, PLA biodegradable bed sheets and PLA biodegradable isolation gowns can be trialled in a single ward before broader rollout.
3. Right-size before you substitute. Choosing the correct absorbency class, pack size and glove type — for example, CliniEco's exam-grade nitrile gloves where clinical protocols allow — reduces material use without compromising protection.
4. Optimize packaging. Packaging can represent a meaningful share of a product's footprint. Prefer concentrated case counts, recyclable or compostable packaging and efficient shipping.
5. Segregate waste at the point of generation. Separate general waste, recyclables, organics and hazardous waste so certified compostable PLA items reach industrial composting where available, and non-infectious materials are not incinerated unnecessarily [16][17]. PLA biodegradable waste bags can support this segregation in patient rooms.
6. Evaluate total cost of ownership. PLA products may carry a modest price premium over conventional disposables, although the gap has narrowed as capacity expands [15]. Compare across the full contract term, including waste treatment and institutional carbon targets.

Limitations and Trade-Offs of Bioplastics

Bio-based materials have limits worth acknowledging. First, land use: PLA feedstock competes with food production, and large-scale expansion raises questions of land-use change and biodiversity [9][14]. Second, agricultural inputs: the fertilizer, water and energy used to grow feedstock can offset part of the climate advantage [9]. Third, recycling contamination: bio-based and biodegradable resins can disrupt conventional recycling streams if not separately collected; the Ellen MacArthur Foundation warns that biodegradable plastics are not a solution to litter and can undermine recycling when poorly managed [21]. Fourth, compostability depends on industrial infrastructure that remains scarce in most Canadian municipalities and virtually absent inside hospitals. Fifth, cost: PLA resin generally commands a premium, though forecasts project rapid capacity growth and falling prices [15]. Finally, degradation in real environments is more variable than laboratory tests suggest [11].

None of these limitations argues against PLA; they argue for careful, LCA-informed selection and for respecting the waste hierarchy, where prevention and reuse remain the priorities and material substitution is a complement, not a substitute, for reducing consumption [21].

Frequently Asked Questions

Is PLA truly biodegradable in the environment?

PLA is compostable under industrial conditions: ASTM D6400 requires at least 90% disintegration and 90% carbon conversion within 180 days at roughly 58°C in a managed facility [10]. Outside those conditions — soil, freshwater, marine environments, a typical home heap — it degrades very slowly [11]. Look for certification such as BPI or TÜV OK Compost [9].

Are PLA-based medical products safe for patient contact?

Biocompatibility is a property of the finished device, not of the raw resin. Products for patient contact should be supported by testing per ISO 10993-1 and by supplier documentation such as certificates of analysis [23]. Request this for any bio-based alternative, exactly as you would for a conventional product.

How much more do PLA products cost?

PLA resin generally carries a premium over polypropylene and polyethylene, although the gap has narrowed as global capacity expands; analysts project double-digit growth in the PLA market through 2030 [15]. A total-cost-of-ownership view — waste treatment, segregation labour, institutional carbon targets — often narrows or reverses the premium.

How can our procurement team verify supplier sustainability claims?

Request environmental product declarations per ISO 14040/14044 [5][6], third-party life-cycle assessments, certifications such as ASTM D6400 [10], and feedstock sourcing documentation. Independent verification is the difference between a claim and an evidence-based decision.

Conclusion

The carbon footprint of medical supplies is neither invisible nor immutable. It is measurable through established LCA methods [5][6], dominated by the raw materials embedded in single-use products [7][20], and reducible through procurement decisions Canadian health-care organizations can make today. The evidence supports a graduated approach: measure first; prevent and right-size second; substitute with certified bio-based materials such as PLA where clinically appropriate; and manage end-of-life so that compostable products reach the infrastructure that realizes their benefit [10][16][17]. A practical starting point is a pilot in a high-volume, low-risk category — underpads, bed sheets, isolation gowns or waste bags — supported by supplier documentation.

References

1. Eckelman MJ, Sherman JD, MacNeill AJ. Life cycle environmental emissions and health damages from the Canadian healthcare system. PLoS Medicine. 2018;15(7). https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002623
2. Health Care Without Harm, Arup. Health care's climate footprint: how the health sector contributes to the global climate crisis and opportunities for action. 2019. https://noharm-global.org/sites/default/files/documents-files/5961/HealthCaresClimateFootprint.pdf
3. World Health Organization. Global road map for health care decarbonization. 2021. https://www.who.int/publications/i/item/9789240031500
4. NHS England. Delivering a 'Net Zero' National Health Service. 2020. https://www.england.nhs.uk/greenernhs/wp-content/uploads/sites/51/2020/10/delivering-a-net-zero-national-health-service.pdf
5. ISO. ISO 14040:2006 — Environmental management — Life cycle assessment — Principles and framework. https://www.iso.org/standard/37456.html
6. ISO. ISO 14044:2006 — Environmental management — Life cycle assessment — Requirements and guidelines. https://www.iso.org/standard/38498.html
7. Vink ETH, Davies S. Life cycle inventory and impact assessment data for 2014 Ingeo polylactide production. Industrial Biotechnology. 2015;11(3). https://www.liebertpub.com/doi/10.1089/ind.2015.0003
8. Taib N-AAB, Rahman MR, Huda D, et al. A review on poly lactic acid (PLA) as a biodegradable polymer. Polymers. 2023;15(5). https://www.mdpi.com/2073-4360/15/5/1198
9. Haider TP, Völker C, Kramm J, Landfester K, Wurm FR. Plastics of the future? The impact of biodegradable polymers on the environment and on society. Angewandte Chemie International Edition. 2019;58(1). https://onlinelibrary.wiley.com/doi/10.1002/anie.201805766
10. ASTM International. ASTM D6400-23 — Standard specification for labeling of plastics designed to be aerobically composted in municipal or industrial facilities. 2023. https://www.astm.org/d6400-23.html
11. Karamanlioglu M, Preziosi R, Robson GD. Abiotic and biotic environmental degradation of the bioplastic polymer poly(lactic acid): a review. Polymer Degradation and Stability. 2017;137. https://www.sciencedirect.com/science/article/pii/S0141391017300688
12. Government of Canada. Single-use Plastics Prohibition Regulations, SOR/2022-136. https://laws-lois.justice.gc.ca/eng/regulations/SOR-2022-136/
13. European Union. Directive (EU) 2019/904 on the reduction of the impact of certain plastic products on the environment. https://eur-lex.europa.eu/eli/dir/2019/904/oj
14. European Bioplastics. Bioplastics market development data. https://www.european-bioplastics.org/market/
15. Grand View Research. Polylactic acid (PLA) market size and trends analysis report, 2024–2030. https://www.grandviewresearch.com/industry-analysis/polylactic-acid-pla-market
16. World Health Organization. Health-care waste. Fact sheet. https://www.who.int/news-room/fact-sheets/detail/health-care-waste
17. IPCC. 2006 IPCC Guidelines for National Greenhouse Gas Inventories, Volume 5: Waste. https://www.ipcc-nggip.iges.or.jp/public/2006gl/vol5.html
18. Vozzola E, Overcash M, Griffing E. Life cycle assessment of isolation gowns used in healthcare. AORN Journal. 2018;107(6). https://aornjournal.onlinelibrary.wiley.com/doi/10.1002/aorn.12148
19. Kourmentza C, Plácido J, Venetsaneas N, et al. Recent advances and challenges towards sustainable polyhydroxyalkanoate (PHA) production. Bioengineering. 2017;4(2). https://www.mdpi.com/2306-5354/4/2/55
20. Rizan C, Steinbach I, Nicholson R, Lillywhite R, Reed M, Bhutta MF. The carbon footprint of surgical operations: a systematic review. Annals of Surgery. 2020;272(6). https://doi.org/10.1097/SLA.0000000000003953
21. Ellen MacArthur Foundation. The new plastics economy: rethinking the future of plastics. 2016. https://www.ellenmacarthurfoundation.org/the-new-plastics-economy-rethinking-the-future-of-plastics
22. Canadian Coalition for Green Health Care. https://greenhealthcare.ca/
23. ISO. ISO 10993-1:2018 — Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process. https://www.iso.org/standard/68936.html
24. Government of Canada. Greening Government Strategy. https://www.canada.ca/en/treasury-board-secretariat/services/innovation/greening-government/strategy.html
25. Selvaranjan K, Navaratnam S, Rajeev P, Ravintherakumaran N. Environmental challenges induced by extensive use of face masks during COVID-19: a review and potential solutions. Environmental Challenges. 2021;3. https://www.sciencedirect.com/science/article/pii/S2667010020300643

Related Reading

Explore more guides in this category:

• Men vs Women: How Absorbency Placement Changes Product Choice
• Wheelchair Users: Openable Briefs and Side-Seam Designs Explained
• Biodegradable Adult Diapers: Eco-Friendly Options in Canada?